Immunochemical detection of advanced glycosylation end products in vivo.
Reducing sugars react with protein amino groups to form a diverse group of protein-bound moieties with fluorescent and cross-linking properties. These compounds, called advanced glycosylation end products (AGEs), have been implicated in the structural and functional alterations of proteins that occur during aging and long-term diabetes. Although several AGEs have been identified on the basis of de novo synthesis and tissue isolation procedures, the measurement of AGE compounds in vivo has remained difficult. As an approach to the study of AGE formation in vivo, we prepared polyclonal antiserum to an AGE epitope(s) which forms in vitro after incubation of glucose with ribonuclease (RNase). This antiserum proved suitable for the detection of AGEs which form in vivo. Both diabetic tissue and serum known to contain elevated levels of AGEs readily competed for antibody binding. Cross-reactivity studies revealed the presence of a common AGE epitope(s) which forms after the incubation of diverse proteins with glucose. Cross-reactive epitopes also formed with glucose 6-phosphate or fructose. These data suggest that tissue AGEs which form in vivo appear to contain a common immunological epitope which cross-reacts with AGEs prepared in vitro, supporting the concept that immunologically similar AGE structures form from the incubation of sugars with different proteins (Horiuchi, S., Araki, N., and Morino, Y. (1991) J. Biol. Chem. 266, 7329-7332). None of the known AGEs, such as 4-furanyl-2-furoyl-1H-imidazole, 1-alkyl-2-formyl-3,4-diglycosylpyrrole, pyrraline, carboxymethyllysine, or pentosidine, were found to compete for binding to anti-AGE antibody. These data further suggest that the dominant AGE epitope which forms from the reaction of glucose with proteins under native conditions is immunologically distinct from the structurally defined AGEs described to date.
Makita
Z
Z
Laboratory of Medical Biochemistry, Rockefeller University, New York, New York 10021.
Vlassara
H
H
Cerami
A
A
Bucala
R
R
D000293:Adolescent; D000818:Animals; D001667:Binding, Competitive; D003094:Collagen / Q000031:analogs & derivatives / Q000032:analysis; D003429:Cross Reactions; D003921:Diabetes Mellitus, Experimental / Q000097:blood*; D003922:Diabetes Mellitus, Type 1 / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D003928:Diabetic Nephropathies / Q000097:blood* / Q000628:therapy; D004797:Enzyme-Linked Immunosorbent Assay; D000939:Epitopes / Q000032:analysis; D005455:Fluorescent Antibody Technique; D006442:Glycated Hemoglobin / Q000032:analysis; D006023:Glycoproteins / Q000032:analysis* / Q000276:immunology; D006031:Glycosylation; D006801:Humans; D007106:Immune Sera; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000628:therapy; D008875:Middle Aged; D051381:Rats; D011917:Rats, Inbred Lew; D012016:Reference Values; D006435:Renal Dialysis
D003094:Collagen; D000939:Epitopes; D006442:Glycated Hemoglobin; D006023:Glycoproteins; D007106:Immune Sera; C022814:glycosylated collagen